EA202192140A1 - СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) - Google Patents

СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)

Info

Publication number
EA202192140A1
EA202192140A1 EA202192140A EA202192140A EA202192140A1 EA 202192140 A1 EA202192140 A1 EA 202192140A1 EA 202192140 A EA202192140 A EA 202192140A EA 202192140 A EA202192140 A EA 202192140A EA 202192140 A1 EA202192140 A1 EA 202192140A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rvwf
methods
preventive treatment
recombinant vwf
subject
Prior art date
Application number
EA202192140A
Other languages
English (en)
Inventor
Бьерн Мельгорд
Брюс ЭВЕНШТАЙН
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA202192140A1 publication Critical patent/EA202192140A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Abstract

Настоящее изобретение относится к способу профилактического лечения спонтанного кровотечения у субъекта с тяжелой формой болезни фон Виллебранда, включающему введение субъекту терапевтического количества рекомбинантного фактора фон Виллебранда (рФВ).
EA202192140A 2019-02-01 2020-01-31 СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ) EA202192140A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962800370P 2019-02-01 2019-02-01
PCT/US2020/016194 WO2020160460A1 (en) 2019-02-01 2020-01-31 Methods of prophylactic treatment using recombinant vwf (rvwf)

Publications (1)

Publication Number Publication Date
EA202192140A1 true EA202192140A1 (ru) 2021-12-15

Family

ID=69740772

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192140A EA202192140A1 (ru) 2019-02-01 2020-01-31 СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)

Country Status (14)

Country Link
US (1) US20200261546A1 (ru)
EP (1) EP3917557A1 (ru)
JP (1) JP2022524291A (ru)
KR (1) KR20210134642A (ru)
CN (1) CN113645993A (ru)
AU (1) AU2020216976A1 (ru)
BR (1) BR112021015068A2 (ru)
CA (1) CA3128498A1 (ru)
CO (1) CO2021011340A2 (ru)
EA (1) EA202192140A1 (ru)
IL (1) IL285220A (ru)
MX (1) MX2021009114A (ru)
SG (1) SG11202108325YA (ru)
WO (1) WO2020160460A1 (ru)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101163506B (zh) 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
LT1974014T (lt) 2006-01-04 2017-11-27 Baxalta Incorporated Ląstelių kultūros terpė be oligopeptidų
US8133865B2 (en) * 2006-12-27 2012-03-13 Nektar Therapeutics von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
EP2601932A1 (en) 2008-10-21 2013-06-12 Baxter International Inc. Lyophilized recombinant VWF formulations
EP3388529A1 (en) * 2008-12-05 2018-10-17 Baxalta GmbH Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof
CA2770609A1 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
CN103097409A (zh) 2010-07-08 2013-05-08 巴克斯特国际公司 在细胞培养物中生产重组高分子量vWF的方法
EP3858375B1 (en) * 2011-06-10 2024-03-20 Takeda Pharmaceutical Company Limited Treatment of coagulation disease by administration of recombinant vwf
WO2015066700A2 (en) * 2013-11-04 2015-05-07 The Regents Of The University Of California Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation
SG11201706659WA (en) * 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life

Also Published As

Publication number Publication date
AU2020216976A1 (en) 2021-09-30
MX2021009114A (es) 2021-10-13
IL285220A (en) 2021-09-30
CN113645993A (zh) 2021-11-12
WO2020160460A1 (en) 2020-08-06
KR20210134642A (ko) 2021-11-10
CA3128498A1 (en) 2020-08-06
SG11202108325YA (en) 2021-08-30
US20200261546A1 (en) 2020-08-20
JP2022524291A (ja) 2022-05-02
BR112021015068A2 (pt) 2021-10-05
CO2021011340A2 (es) 2021-09-20
EP3917557A1 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
BR112018010160A2 (pt) inibidor da c1 esterase humana recombinante e usos do mesmo
CO2020014566A2 (es) Métodos de tratamiento de la hemofilia a
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
MX2017014503A (es) Polipeptidos de factor de von willebrand truncado para tratar hemofilia.
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
MY194448A (en) Short synthetic peptide for treating diseases and/or conditions related to angiogenesis
EA201791525A3 (ru) Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w
EA202090705A1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
CY1124339T1 (el) Φαρμακευτικη συνθεση παρατεταμενης αποδεσμευσης η οποια εμπεριεχει ριβαστιγμινη
EA202192140A1 (ru) СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
PH12015502100A1 (en) Reducing the risk of autoimmune disease
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
MX2018001684A (es) Metodo de curacion de heridas.
PH12015502037B1 (en) Activating adiponectin by casein hydrolysate
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
CA2898975C (en) Inhibition of tissue factor pathway inhibitor with factor xa derivatives
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
NZ734845A (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
PH12017501918A1 (en) Multi-peptide composition